Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Knoll Pharma: Other income buoys net - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Feb 23, 2001

    Knoll Pharma: Other income buoys net

    Knoll Pharma has reported a 5% jump in the net profit on the back of a 14.3% jump in the turnover. Even last year the company derived a substantial portion of its revenues from other income. Thus on a like to like basis, the profit growth has been an impressive 55%, if one were to exclude the non–recurring other income in both the years after adjusting the tax paid on that.

    Over the last two years the company has been restructuring its Indian operations. It has shut down its Sion plant, paid off its workers (via a VRS) and consolidated operations at its Jejuri plant (in Maharashtra) and its Goa plant.

    (Rs m) FY00 FY01 Change
    Sales 2,910 3,333 14.5%
    Other Income 110 310 182.6%
    Profit after Tax/(Loss) 685 722 5.4%
    Net profit margin (%) 23.5% 21.7%  
    Earnings per share 42.28 44.57  

    The company also renegotiated the deal for the sale of its Sion premises during last year. (This was because after paying an advance of Rs 254.5 m for the plot, the buyer, Neo–Pharma expressed its inability to proceed with the transaction. The plot was split into two and one part was given to Neo–Pharma with Knoll allowed to sell the second plot to a new buyer.) It is the deal for the second plot that has gone through and the company has derived a profit on the sale of this property for Rs 131 m.

    The company is a leader in the anti–diabetes segment with a market share of more than 70%. (Hoechst Marion Roussel is the company’s closest competitor in this segment.) The company’s insulin business contributes around 40% of the company’s turnover. The incidence of diabetes in India is very high. However, given the low income levels, the percentage of untreated diabetic patients in India is very high. And as more and more patients come under the umbrella of diabetes treatment, the insulin market should see a healthy growth.

    However, the company’s other products Brufen and Digene have registered volume declines over the last two years. The stock quotes at a price of Rs 336, which implies an earnings multiple of 10 times (excluding the non recurring other income).

    Perhaps, the only grey area is the apprehension (which is common to all MNC pharmaceutical companies) that the parent may in the future introduce new products only through a 100% subsidiary. Another development that could create uncertainty is the anticipated merger with Abbott India after its parent Knoll AG was acquired by Abbott Inc.



    Equitymaster requests your view! Post a comment on "Knoll Pharma: Other income buoys net ". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts